Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Phase
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
-
Aalst, Belgien, 9300
- GSK Investigational Site
-
Brasschaat, Belgien, 2930
- GSK Investigational Site
-
Bruxelles, Belgien, 1200
- GSK Investigational Site
-
Gent, Belgien, 9000
- GSK Investigational Site
-
-
-
-
Baden-Wuerttemberg
-
Freiburg, Baden-Wuerttemberg, Deutschland, 79110
- GSK Investigational Site
-
-
Hessen
-
Marburg, Hessen, Deutschland, 35043
- GSK Investigational Site
-
-
Mecklenburg-Vorpommern
-
Neubrandenburg, Mecklenburg-Vorpommern, Deutschland, 17036
- GSK Investigational Site
-
Rostock, Mecklenburg-Vorpommern, Deutschland, 18059
- GSK Investigational Site
-
Schwerin, Mecklenburg-Vorpommern, Deutschland, 19055
- GSK Investigational Site
-
Wismar, Mecklenburg-Vorpommern, Deutschland, 23966
- GSK Investigational Site
-
-
Rheinland-Pfalz
-
Ludwigshafen, Rheinland-Pfalz, Deutschland, 67063
- GSK Investigational Site
-
-
Saarland
-
Homburg, Saarland, Deutschland, 66421
- GSK Investigational Site
-
-
Sachsen-Anhalt
-
Halle, Sachsen-Anhalt, Deutschland, 06120
- GSK Investigational Site
-
-
Schleswig-Holstein
-
Kiel, Schleswig-Holstein, Deutschland, 24105
- GSK Investigational Site
-
-
-
-
-
Kwun Tong, Hongkong
- GSK Investigational Site
-
Pokfulam, Hongkong
- GSK Investigational Site
-
Shatin, New Territories, Hongkong
- GSK Investigational Site
-
Sheung Shui, New Territories, Hongkong
- GSK Investigational Site
-
-
-
-
Ontario
-
Toronto, Ontario, Kanada, M5G 2M9
- GSK Investigational Site
-
Toronto, Ontario, Kanada, M5G 1X5
- GSK Investigational Site
-
-
Quebec
-
Sainte-Foy, Quebec, Kanada, G1V 4G2
- GSK Investigational Site
-
Sherbrooke, Quebec, Kanada, J1H 5N4
- GSK Investigational Site
-
-
-
-
-
Lahore, Pakistan
- GSK Investigational Site
-
-
-
-
-
Manila, Philippinen, 1000
- GSK Investigational Site
-
Quezon, City, Philippinen, 1104
- GSK Investigational Site
-
-
-
-
-
Moscow, Russische Föderation, 101000
- GSK Investigational Site
-
Moscow, Russische Föderation, 111538
- GSK Investigational Site
-
Moscow, Russische Föderation, 117152
- GSK Investigational Site
-
Perm, Russische Föderation, 614107
- GSK Investigational Site
-
St. Petersburgh, Russische Föderation, 192242
- GSK Investigational Site
-
-
-
-
-
Badalona, Spanien, 08916
- GSK Investigational Site
-
Barcelona, Spanien, 08025
- GSK Investigational Site
-
Barcelona, Spanien, 08035
- GSK Investigational Site
-
Barcelona, Spanien, 08003
- GSK Investigational Site
-
La Coruña, Spanien, 15006
- GSK Investigational Site
-
Mataro, Spanien, 08034
- GSK Investigational Site
-
Pamplona, Spanien, 31008
- GSK Investigational Site
-
Santiago de Compostela, Spanien, 15706
- GSK Investigational Site
-
-
-
-
-
Bangkok, Thailand
- GSK Investigational Site
-
-
-
-
-
Brno, Tschechische Republik, 625 00
- GSK Investigational Site
-
Jihlava, Tschechische Republik, 586 01
- GSK Investigational Site
-
Olomouc, Tschechische Republik, 775 20
- GSK Investigational Site
-
Pardubice, Tschechische Republik, 532 03
- GSK Investigational Site
-
Praha 2, Tschechische Republik, 128 51
- GSK Investigational Site
-
Praha 5, Tschechische Republik, 150 08
- GSK Investigational Site
-
-
-
-
Alabama
-
Fairhope, Alabama, Vereinigte Staaten, 36532
- GSK Investigational Site
-
Mobile, Alabama, Vereinigte Staaten, 36608
- GSK Investigational Site
-
Montgomery, Alabama, Vereinigte Staaten, 36106
- GSK Investigational Site
-
-
Arkansas
-
Little Rock, Arkansas, Vereinigte Staaten, 72205
- GSK Investigational Site
-
-
California
-
Arcadia, California, Vereinigte Staaten, 91007
- GSK Investigational Site
-
Glendale, California, Vereinigte Staaten, 91206
- GSK Investigational Site
-
Laguna Hills, California, Vereinigte Staaten, 92653
- GSK Investigational Site
-
Pasadena, California, Vereinigte Staaten, 91105
- GSK Investigational Site
-
-
Florida
-
Boca Raton, Florida, Vereinigte Staaten, 33067
- GSK Investigational Site
-
Melbourne, Florida, Vereinigte Staaten, 32901
- GSK Investigational Site
-
Miami, Florida, Vereinigte Staaten, 33143
- GSK Investigational Site
-
West Palm Beach, Florida, Vereinigte Staaten, 33409
- GSK Investigational Site
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60637
- GSK Investigational Site
-
-
Kansas
-
Kansas City, Kansas, Vereinigte Staaten, 66160
- GSK Investigational Site
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21229-5299
- GSK Investigational Site
-
-
Michigan
-
Royal Oak, Michigan, Vereinigte Staaten, 48073
- GSK Investigational Site
-
-
New York
-
Mineola, New York, Vereinigte Staaten, 11501
- GSK Investigational Site
-
New Hyde Park, New York, Vereinigte Staaten, 11040
- GSK Investigational Site
-
New York, New York, Vereinigte Staaten, 10038
- GSK Investigational Site
-
-
North Carolina
-
Winston-Salem, North Carolina, Vereinigte Staaten, 27103
- GSK Investigational Site
-
-
Ohio
-
Cincinnati, Ohio, Vereinigte Staaten, 45208
- GSK Investigational Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Vereinigte Staaten, 73104
- GSK Investigational Site
-
-
Virginia
-
Charlottesville, Virginia, Vereinigte Staaten, 22908
- GSK Investigational Site
-
Winchester, Virginia, Vereinigte Staaten, 22601
- GSK Investigational Site
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98195
- GSK Investigational Site
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion criteria:
- History of PONV (postoperative nausea and vomiting) and/or motion sickness.
- Have not smoked for the last 6 months.
- Having certain abdominal, breast, thyroid or shoulder surgery.
Exclusion criteria:
- Pregnant or breastfeeding.
- Have certain pre-existing medical conditions or take certain medications.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of participants who achieved a complete response
Zeitfenster: Up to 24 hours
|
Complete response defined as no vomiting or retching and no rescue therapy during the first 24 hours following placement of the last suture/staple.
Vomiting defined as the forceful expulsion of gastrointestinal contents through the mouth or nose.
Retching defined as the labored, spasmodic, rhythmic contraction of the respiratory and abdominal muscles in an attempt to vomit that is not productive of gastrointestinal contents (also known as "dry heaves").
Study participants who receive antiemetic rescue medication(s) during the initial 24 hours was considered treatment failures.
|
Up to 24 hours
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
The severity of nausea experienced by participants in each cohort during the 2, 6, 24 and 48 hour periods, as assessed by an 11-point, linear, numerical rating scale referred to as a "0-10 Likert scale"
Zeitfenster: Up to 48 hours
|
Nausea is defined as a subjectively unpleasant sensation associated with the awareness of the urge to vomit; the desire to vomit without the presence of expulsive muscular movements.
Each participant completed a Likert scale at 2, 6, 24 and 48 hours after placement of the last suture/staple.
The Likert scale used a range of 0-10, where 0 = no nausea and 10 = nausea as bad as it could be.
|
Up to 48 hours
|
|
The severity of nausea experienced by participants in each cohort during the 2, 6, 24 and 48 hour periods, as assessed by a categorical scale (none, mild, moderate or severe), as defined in the protocol
Zeitfenster: Up to 48 hours
|
Nausea is defined as a subjectively unpleasant sensation associated with the awareness of the urge to vomit; the desire to vomit without the presence of expulsive muscular movements.
Each participant completed a categorical scale at 2, 6, 24 and 48 hours after placement of the last suture/staple.
In the categorical scale, each participant asked to rate the severity of nausea as, none: no nausea, mild: queasiness/upset stomach that is manageable and minimally (if at all) affects daily activities, moderate: increased queasiness, sometimes with the feeling of having to vomit (but not vomiting), that has a significant negative effect on daily activities (for example, being unable to work, eat and drink, prepare food, care for children or others), severe: feeling sick and vomiting or feeling like you are going to vomit, and unable to perform most daily activities.
|
Up to 48 hours
|
|
Number of participants with first emetic event
Zeitfenster: Up to 48 hours
|
Up to 48 hours
|
|
|
Number of participants with first antiemetic rescue medication
Zeitfenster: Up to 48 hours
|
Up to 48 hours
|
|
|
Participant satisfaction with the prophylactic antiemetic regimens, as assessed by participant satisfaction assessments in the participant diary
Zeitfenster: Up to 48 hours
|
Up to 48 hours
|
|
|
Participant willingness of participants to use the same treatment regimen for future surgical procedures, as assessed by participant satisfaction assessments in the participant diary
Zeitfenster: Up to 48 hours
|
Up to 48 hours
|
|
|
Number of participants with chemistry data outside the reference range
Zeitfenster: Up to 48 hours
|
Up to 48 hours
|
|
|
Number of participants with hematology data outside the reference range
Zeitfenster: Up to 48 hours
|
Up to 48 hours
|
|
|
Safety and tolerability of the antiemetic regimens, assessed by clinical observation (including time to awakening from anesthesia, defined as ability to respond to a verbal command)
Zeitfenster: Up to 24 hours
|
Up to 24 hours
|
|
|
Number of participants with adverse events (AEs) and serious adverse events (SAEs)
Zeitfenster: Up to Days 6-14 visit
|
An AE was defined as any untoward medical occurrence (MO) in a participant temporally associated with the use of a medicinal product (MP), whether or not considered related to the MP and can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with its use.
The SAE was any untoward MO that, at any dose, results in death, life threatening, persistent or significant disability/incapacity, results in or prolongs inpatient hospitalization, congenital abnormality or birth defect, that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in this definition.
Refer to the general AE/SAE module for a list of AEs and SAEs.
|
Up to Days 6-14 visit
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Pathologische Prozesse
- Postoperative Komplikationen
- Anzeichen und Symptome, Verdauungstrakt
- Brechreiz
- Erbrechen
- Postoperative Übelkeit und Erbrechen
- Physiologische Wirkungen von Arzneimitteln
- Neurotransmitter-Agenten
- Molekulare Mechanismen der pharmakologischen Wirkung
- Autonome Agenten
- Agenten des peripheren Nervensystems
- Antiemetika
- Magen-Darm-Mittel
- Neurokinin-1-Rezeptorantagonisten
- Casopitant
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- NKT102552
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Studiendaten/Dokumente
-
Datensatzspezifikation
Informationskennung: NKT102552Informationskommentare: For additional information about this study please refer to the GSK Clinical Study Register
-
Einzelner Teilnehmerdatensatz
Informationskennung: NKT102552Informationskommentare: For additional information about this study please refer to the GSK Clinical Study Register
-
Kommentiertes Fallberichtsformular
Informationskennung: NKT102552Informationskommentare: For additional information about this study please refer to the GSK Clinical Study Register
-
Einwilligungserklärung
Informationskennung: NKT102552Informationskommentare: For additional information about this study please refer to the GSK Clinical Study Register
-
Studienprotokoll
Informationskennung: NKT102552Informationskommentare: For additional information about this study please refer to the GSK Clinical Study Register
-
Klinischer Studienbericht
Informationskennung: NKT102552Informationskommentare: For additional information about this study please refer to the GSK Clinical Study Register
-
Statistischer Analyseplan
Informationskennung: NKT102552Informationskommentare: For additional information about this study please refer to the GSK Clinical Study Register
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .